# Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT05322330** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Flu
- **DRUG:** CTX
- **DRUG:** CAR-T

## Key facts

- **NCT ID:** NCT05322330
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-10
- **Primary completion:** 2024-02-10
- **Final completion:** 2024-02-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-02-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322330, "Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05322330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*